Theraclion announced that on May 24, the Board of Directors appointed Martin Deterre as CEO, previously Director of Engineering and Development of Theraclion since 2020. He has successfully led the development of the new generations of SONOVEIN® and demonstrated his ability to achieve ambitious goals in a short timeframe with dynamism and pragmatism.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 EUR | -1.10% | +4.35% | -7.22% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.22% | 17.42M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- ALTHE Stock
- News Theraclion
- Theraclion Appoints Martin Deterre as CEO